Maravai LifeSciences, a transformative company in the life science research market, today announced that it has acquired Sterling, Va-based Glen Research Corporation. Founded in 1987, Glen Research is a leader in providing a wide range of reagents used in the synthesis of DNA and RNA. The acquisition fits with Maravai LifeSciences’ goal of creating a market-leading life science business by bringing investment, strong and experienced leadership, processes and best practices to companies with notable growth potential.
David Weber, vice president and chief commercial officer for Maravai LifeSciences, commented, “We’re excited to partner with the Glen Research team. The acquisition supports our commitment to the genomics market, which we first entered with the acquisition of TriLink BioTechnologies last year. Glen Research’s commitment to quality and customer service fits perfectly with the Maravai LifeSciences brand.”
Hugh Mackie, founder and CEO of Glen Research, noted, “We are pleased to have found a partner who shares our values and intends to preserve and extend Glen Research’s commitment to our customers. We look forward to this next phase in our growth as part of Maravai LifeSciences.”
Maravai LifeSciences provides reagents and services to life science researchers and commercial partners to enable breakthrough discoveries and improvements in human health. Maravai Life Sciences’ products are used broadly by academic researchers investigating cancer and other diseases, firms developing new genetic therapies, biopharmaceutical partners validating and monitoring manufacturing processes and by OEM partners who incorporate Maravai offerings into their own products. The Maravai portfolio focuses on bioprocess impurity testing, oligonucleotide synthesis and protein detection. In addition to Glen Research, the Maravai LifeSciences portfolio of companies now includes TriLink BioTechnologies, Vector Laboratories and Cygnus Technologies. Maravai LifeSciences is a portfolio company of GTCR, a leading private equity firm focused on investing in growth companies in healthcare, technology and information services and financial services.
David Weber, Chief Commercial Officer